A non-steroidal fertility drug called clomiphene is used to trigger ovulation in women who ovulate infrequently or don’t ovulate at all, including those with polycystic ovary syndrome (PCOS). Patients with an intact hypothalamic-pituitary-ovarian axis and ovaries capable of normal function can use the medication to induce ovulation. Due to its ease of use and inexpensive cost, clomiphene is frequently the first-line treatment for these patients. 80 percent of individuals who are properly selected will experience ovulation induction with clomiphene; around 40 percent of these patients will become pregnant within 6 cycles of treatment. Women who naturally ovulate on a regular cycle and take clomiphene do not experience an increase in pregnancy rates. Compared to the general population, clomiphene treatment is associated with only marginally higher rates of multiple births (3–5%). (1 percent ). If multiple gestation happens, it frequently results in twins. Less than 1% of women give birth to triplets or more. When used as a single agent, clomiphene has a substantially lower rate of multiparity than other fertility drugs (e.g., menotropins or FSH). Ovarian reserve can occasionally be determined using clomiphene as a diagnostic technique. In patients undergoing donor insemination, it is also used to control the timing of ovulation. It’s interesting to note that clomiphene has been applied to male patients with idiopathic oligospermia to improve sperm counts. Clomiphene was initially given FDA approval in 1967.